Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Non-Current Liabilities: 2020-2024

Historic Total Non-Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 4 years, with Dec 2024 value amounting to $648.5 million.

  • Apellis Pharmaceuticals' Total Non-Current Liabilities fell 0.09% to $654.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $654.3 million, marking a year-over-year decrease of 0.09%. This contributed to the annual value of $648.5 million for FY2024, which is 9.57% up from last year.
  • Apellis Pharmaceuticals' Total Non-Current Liabilities amounted to $648.5 million in FY2024, which was up 9.57% from $591.9 million recorded in FY2023.
  • Apellis Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $648.5 million during FY2024, with a 5-year trough of $338.0 million in FY2021.
  • In the last 2 years, Apellis Pharmaceuticals' Total Non-Current Liabilities had a median value of $620.2 million in 2023 and averaged $620.2 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Total Non-Current Liabilities plummeted by 32.73% in 2021, and later increased by 9.57% in 2024.
  • Over the past 4 years, Apellis Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $502.4 million in 2020, then crashed by 32.73% to $338.0 million in 2021, then reached $591.9 million in 2023, then grew by 9.57% to $648.5 million in 2024.